- Home
- GDL vs CRDL Comparison
GDL vs CRDL Comparison
Compare GDL & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- CRDL
- Stock Information
- Founded
- GDL 2006
- CRDL 2017
- Country
- GDL United States
- CRDL Canada
- Employees
- GDL N/A
- CRDL N/A
- Industry
- GDL Investment Managers
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDL Finance
- CRDL Health Care
- Exchange
- GDL Nasdaq
- CRDL Nasdaq
- Market Cap
- GDL 95.6M
- CRDL 90.4M
- IPO Year
- GDL N/A
- CRDL N/A
- Fundamental
- Price
- GDL $8.52
- CRDL $1.07
- Analyst Decision
- GDL
- CRDL Strong Buy
- Analyst Count
- GDL 0
- CRDL 2
- Target Price
- GDL N/A
- CRDL $9.00
- AVG Volume (30 Days)
- GDL 11.2K
- CRDL 781.9K
- Earning Date
- GDL 01-01-0001
- CRDL 11-13-2025
- Dividend Yield
- GDL 6.02%
- CRDL N/A
- EPS Growth
- GDL N/A
- CRDL N/A
- EPS
- GDL N/A
- CRDL N/A
- Revenue
- GDL N/A
- CRDL N/A
- Revenue This Year
- GDL N/A
- CRDL N/A
- Revenue Next Year
- GDL N/A
- CRDL N/A
- P/E Ratio
- GDL N/A
- CRDL N/A
- Revenue Growth
- GDL N/A
- CRDL N/A
- 52 Week Low
- GDL $7.65
- CRDL $0.77
- 52 Week High
- GDL $8.13
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- GDL 54.41
- CRDL 44.27
- Support Level
- GDL $8.51
- CRDL $1.04
- Resistance Level
- GDL $8.59
- CRDL $1.16
- Average True Range (ATR)
- GDL 0.07
- CRDL 0.06
- MACD
- GDL -0.00
- CRDL 0.00
- Stochastic Oscillator
- GDL 73.68
- CRDL 18.00
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.